Search results
Analyst Report: Regeneron Pharmaceuticals, Inc.
Morningstar Research via Yahoo Finance· 5 hours agoRegeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products ...
Roche’s VABYSMO has successful Q1 sales despite Regeneron and Bayer’s EYLEA HD launch
Pharmaceutical Technology via Yahoo Finance· 5 days agoLast week, Roche released promising first-quarter (Q1) 2024 sales figures for VABYSMO, a vascular...
Can At-Home Vision Tests Detect Active Neovascular AMD?
MedPage Today· 4 days agoThree at-home vision-monitoring tools failed to detect worsening neovascular age-related macular ...
EYLEA HD shows promise in long-term clinical trials By Investing.com
Investing.com· 6 days agoHD clinical program during a series of presentations at the Association for Research in Vision and...
...Application for EB-105 - A Novel Trispecific Fusion Antibody for Diabetic Macular Edema (DME) -...
WKRN Nashville· 6 days agoEluminex Biosciences (Eluminex), a privately-held biotechnology company focused on the development of advanced protein therapeutics for vision-threatening diseases and dermal facial aesthetics ...
Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024 - Ocular...
Benzinga· 5 days agoTherapeutix, Inc. OCUL "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative ...
Should You Consider Regeneron (REGN) Ahead of Q1 Earnings?
Zacks via Yahoo Finance· 6 days agoAn increase in profits from Dupixent and further uptake of Eylea HD are likely to have aided...
Kodiak Sciences Inc. (NASDAQ:KOD) Given Average Rating of “Reduce” by Analysts
ETF DAILY NEWS· 5 days agoKodiak Sciences Inc. (NASDAQ:KOD – Get Free Report) has been assigned an average rating of “Reduce” from the seven brokerages that are currently covering the stock, Marketbeat reports. Three ...
Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
Zacks via Yahoo Finance· 4 days agoIn August 2023, the FDA approved Eylea HD (higher dose of Eylea) for the treatment of patients with ...
Head to Head Survey: Cognition Therapeutics (NASDAQ:CGTX) vs. Opthea (NASDAQ:OPT)
ETF DAILY NEWS· 1 day agoCognition Therapeutics (NASDAQ:CGTX – Get Free Report) and Opthea (NASDAQ:OPT – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the ...
